← 返回

CAR-T 细胞治疗与重症监护:医疗急救团队的生存指南

英文原题:CAR T-cell therapy and critical care : A survival guide for medical emergency teams.

查看英文原题

CAR T-cell therapy and critical care : A survival guide for medical emergency teams.

PubMed 2021/10/06(内容时间) Wien Klin Wochenschr Q2 · IF 2.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞经过基因工程改造,使T细胞能够攻击特定的癌细胞,并改善难治/复发性侵袭性B细胞恶性肿瘤患者的结局。迄今为止,已有几种CAR-T 细胞产品获批,其他具有类似适应症或扩展至其他恶性肿瘤的产品目前正在评估中。CAR-T 细胞治疗的副作用可能是严重甚至危及生命的免疫相关毒性,特别是细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)。因此,医疗急救团队(MET)越来越多地参与CAR-T 细胞接受者的评估和管理。本文描述了CAR-T 细胞治疗的原理,并总结了主要并发症及相应的治疗干预措施,旨在为MET提供一份生存指南,并提出管理算法。

展开英文摘要原文

Chimeric antigen receptor (CAR) T cells are genetically engineered to give T cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B cell malignancies. To date, several CAR T cell products are approved and additional products with similar indication or extended to other malignancies are currently being evaluated.

Side effects of CAR T cell treatment are potentially severe or even life-threatening immune-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Consequently, medical emergency teams (MET) are increasingly involved in the assessment and management of CAR T cell recipients. This article describes the principles of CAR T cell therapy and summarizes the main complications and subsequent therapeutic interventions aiming to provide a survival guide for METs with a proposed management algorithm.

论文信息

作者
Messmer AS、Que YA、Schankin C、Banz Y、Bacher U、Novak U、Pabst T
单位
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland. anna.messmer@insel.ch.Switzerland
文献类型
综述
期刊
Wiener klinische Wochenschrift2021 Dec
原文标识
PubMed 34613477 · DOI 10.1007/s00508-021-01948-2